Class information for:
Level 1: AROMATASE INHIBITORS//AROMATASE INHIBITOR//ANASTROZOLE

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
4960 1696 40.0 80%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
0 4 BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY 4064930
159 3       MENOPAUSE//ISOFLAVONES//TAMOXIFEN 61134
329 2             TAMOXIFEN//ESTROGEN RECEPTOR//AROMATASE INHIBITORS 18133
4960 1                   AROMATASE INHIBITORS//AROMATASE INHIBITOR//ANASTROZOLE 1696

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 AROMATASE INHIBITORS authKW 1685576 18% 31% 300
2 AROMATASE INHIBITOR authKW 695777 10% 23% 168
3 ANASTROZOLE authKW 687579 7% 31% 125
4 EXEMESTANE authKW 537990 5% 34% 89
5 LETROZOLE authKW 476077 8% 21% 129
6 ADJUVANT ENDOCRINE THERAPY authKW 464075 2% 66% 39
7 TAMOXIFEN authKW 423473 19% 7% 318
8 ENDOCRINE THERAPY authKW 325678 7% 16% 112
9 OVARIAN ABLATION authKW 272864 1% 63% 24
10 EARLY BREAST CANCER authKW 264166 5% 18% 82

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with term
in class
1 Oncology 34376 72% 0% 1228
2 Obstetrics & Gynecology 2673 13% 0% 214
3 Endocrinology & Metabolism 261 6% 0% 102
4 Medicine, General & Internal 232 7% 0% 120
5 Health Care Sciences & Services 164 3% 0% 43
6 Nursing 75 2% 0% 26
7 Geriatrics & Gerontology 26 1% 0% 16
8 Pharmacology & Pharmacy 21 5% 0% 84
9 Rehabilitation 19 1% 0% 19
10 Public, Environmental & Occupational Health 18 3% 0% 48

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 SENOL EASTERN SWITZERLAND 94698 1% 48% 11
2 IBCSG STAT 86162 1% 32% 15
3 FRENCH BREAST CANC GRP 72010 0% 100% 4
4 INT BREAST CANC STUDY GRP STAT 67850 0% 54% 7
5 GYNECOL ENDOCRINOL ONCOL 64292 0% 71% 5
6 ENDOCRINOL REPROD MED OSTEOPOROSIS 64282 1% 36% 10
7 AUSTRALIAN NEW ZEALAND BREAST CANC TRIALS GRP 60494 1% 31% 11
8 CANC GENET PREVENT SCREENING 54008 0% 100% 3
9 DANISH BREAST CANC GRP 54008 0% 100% 3
10 UNIT CLIN ONCOL 45880 1% 10% 25

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 BREAST 57582 5% 4% 88
2 BREAST CANCER RESEARCH AND TREATMENT 50118 8% 2% 142
3 CLINICAL BREAST CANCER 39378 2% 5% 41
4 BREAST CARE 19692 1% 4% 25
5 JOURNAL OF CLINICAL ONCOLOGY 17842 7% 1% 127
6 ANNALS OF ONCOLOGY 13241 5% 1% 78
7 JOURNAL OF BONE ONCOLOGY 10459 0% 7% 8
8 CANCER TREATMENT REVIEWS 6225 2% 1% 26
9 BREAST CANCER RESEARCH 5562 2% 1% 26
10 ONCOLOGY-NEW YORK 4869 1% 1% 20

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 AROMATASE INHIBITORS 1685576 18% 31% 300 Search AROMATASE+INHIBITORS Search AROMATASE+INHIBITORS
2 AROMATASE INHIBITOR 695777 10% 23% 168 Search AROMATASE+INHIBITOR Search AROMATASE+INHIBITOR
3 ANASTROZOLE 687579 7% 31% 125 Search ANASTROZOLE Search ANASTROZOLE
4 EXEMESTANE 537990 5% 34% 89 Search EXEMESTANE Search EXEMESTANE
5 LETROZOLE 476077 8% 21% 129 Search LETROZOLE Search LETROZOLE
6 ADJUVANT ENDOCRINE THERAPY 464075 2% 66% 39 Search ADJUVANT+ENDOCRINE+THERAPY Search ADJUVANT+ENDOCRINE+THERAPY
7 TAMOXIFEN 423473 19% 7% 318 Search TAMOXIFEN Search TAMOXIFEN
8 ENDOCRINE THERAPY 325678 7% 16% 112 Search ENDOCRINE+THERAPY Search ENDOCRINE+THERAPY
9 OVARIAN ABLATION 272864 1% 63% 24 Search OVARIAN+ABLATION Search OVARIAN+ABLATION
10 EARLY BREAST CANCER 264166 5% 18% 82 Search EARLY+BREAST+CANCER Search EARLY+BREAST+CANCER

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref.
in cl.		 Shr. of ref. in
cl.		 Citations
1 BURSTEIN, HJ , PRESTRUD, AA , SEIDENFELD, J , ANDERSON, H , BUCHHOLZ, TA , DAVIDSON, NE , GELMON, KE , GIORDANO, SH , HUDIS, CA , MALIN, J , ET AL (2010) AMERICAN SOCIETY OF CLINICAL ONCOLOGY CLINICAL PRACTICE GUIDELINE: UPDATE ON ADJUVANT ENDOCRINE THERAPY FOR WOMEN WITH HORMONE RECEPTOR-POSITIVE BREAST CANCER.JOURNAL OF CLINICAL ONCOLOGY. VOL. 28. ISSUE 23. P. 3784-3796 55 75% 319
2 FREEDMAN, OC , FLETCHER, GG , GANDHI, S , MATES, M , DENT, SF , TRUDEAU, ME , EISEN, A , (2015) ADJUVANT ENDOCRINE THERAPY FOR EARLY BREAST CANCER: A SYSTEMATIC REVIEW OF THE EVIDENCE FOR THE 2014 CANCER CARE ONTARIO SYSTEMIC THERAPY GUIDELINE.CURRENT ONCOLOGY. VOL. 22. ISSUE . P. S95 -S113 69 72% 11
3 MURPHY, CC , BARTHOLOMEW, LK , CARPENTIER, MY , BLUETHMANN, SM , VERNON, SW , (2012) ADHERENCE TO ADJUVANT HORMONAL THERAPY AMONG BREAST CANCER SURVIVORS IN CLINICAL PRACTICE: A SYSTEMATIC REVIEW.BREAST CANCER RESEARCH AND TREATMENT. VOL. 134. ISSUE 2. P. 459 -478 55 75% 99
4 LINTERMANS, A , NEVEN, P , (2015) SAFETY OF AROMATASE INHIBITOR THERAPY IN BREAST CANCER.EXPERT OPINION ON DRUG SAFETY. VOL. 14. ISSUE 8. P. 1201 -1211 72 68% 2
5 MOON, Z , MOSS-MORRIS, R , HUNTER, MS , CARLISLE, S , HUGHES, LD , (2017) BARRIERS AND FACILITATORS OF ADJUVANT HORMONE THERAPY ADHERENCE AND PERSISTENCE IN WOMEN WITH BREAST CANCER: A SYSTEMATIC REVIEW.PATIENT PREFERENCE AND ADHERENCE. VOL. 11. ISSUE . P. 305 -322 60 72% 0
6 TREMOLLIERES, FA , (2014) SCREENING FOR OSTEOPOROSIS AFTER BREAST CANCER: FOR WHOM, WHY AND WHEN.MATURITAS. VOL. 79. ISSUE 3. P. 343 -348 47 89% 0
7 SCHIAVON, G , SMITH, IE , (2014) STATUS OF ADJUVANT ENDOCRINE THERAPY FOR BREAST CANCER.BREAST CANCER RESEARCH. VOL. 16. ISSUE 2. P. - 56 63% 17
8 TREMOLLIERES, FA , CEAUSU, L , DEPYPERE, H , LAMBRINOUDAKI, I , MUECK, A , PEREZ-LOPEZ, FR , VAN DER SCHOUW, YT , SENTURK, LM , SIMONCINI, T , STEVENSON, JC , ET AL (2017) OSTEOPOROSIS MANAGEMENT IN PATIENTS WITH BREAST CANCER: EMAS POSITION STATEMENT.MATURITAS. VOL. 95. ISSUE . P. 65 -71 44 86% 0
9 CHLEBOWSKI, RT , KIM, J , HAQUE, R , (2014) ADHERENCE TO ENDOCRINE THERAPY IN BREAST CANCER ADJUVANT AND PREVENTION SETTINGS.CANCER PREVENTION RESEARCH. VOL. 7. ISSUE 4. P. 378 -387 49 70% 18
10 LOMBARD, JM , ZDENKOWSKI, N , WELLS, K , BECKMORE, C , REABY, L , FORBES, JF , CHIRGWIN, J , (2016) AROMATASE INHIBITOR INDUCED MUSCULOSKELETAL SYNDROME: A SIGNIFICANT PROBLEM WITH LIMITED TREATMENT OPTIONS.SUPPORTIVE CARE IN CANCER. VOL. 24. ISSUE 5. P. 2139 -2146 35 90% 2

Classes with closest relation at Level 1


Rank Class id link
1 28301 ORAL CHEMOTHERAPY//ORAL ANTICANCER AGENTS//ORAL ANTICANCER DRUGS
2 5097 AROMATASE INHIBITORS//ANASTROZOLE//EXEMESTANE
3 19527 ENDOXIFEN//TAMOXIFEN//N DESMETHYLTAMOXIFEN
4 10428 BAZEDOXIFENE//RALOXIFENE//TISSUE SELECTIVE ESTROGEN COMPLEX
5 7620 FULVESTRANT//ENDOCRINE RESISTANCE//FASLODEX
6 6521 TAMOXIFEN//TOREMIFENE//ANTIESTROGEN
7 21758 VERY YOUNG WOMEN//YOUNG WOMEN//YOUNG AGE
8 853 TRIPLE NEGATIVE BREAST CANCER//TRIPLE NEGATIVE//ONCOTYPE DX
9 1643 BONE METASTASES//SKELETAL RELATED EVENTS//BONE METASTASIS
10 33403 HYPOTHETICAL REGIMEN//ABSOLUTE SURVIVAL ADVANTAGE//AGIN STUDIES

Go to start page